Systemic Juvenile Idiopathic Arthritis Clinical Trials in Botucatu

A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (sJIA)